JP2022533030A - 抗ｃｇｒｐ抗体を用いた頭痛の治療 - Google Patents

抗ｃｇｒｐ抗体を用いた頭痛の治療 Download PDF

Info

Publication number
JP2022533030A
JP2022533030A JP2021564691A JP2021564691A JP2022533030A JP 2022533030 A JP2022533030 A JP 2022533030A JP 2021564691 A JP2021564691 A JP 2021564691A JP 2021564691 A JP2021564691 A JP 2021564691A JP 2022533030 A JP2022533030 A JP 2022533030A
Authority
JP
Japan
Prior art keywords
administration
seq
hours
migraine
cgrp antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021564691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533030A5 (enExample
Inventor
キャディー，ロジャー，ケー．
スミス，ジェフリー，ティー．エル．
ハーマン，ジョセフ
シェフラー，バーバラ
メータ，ラハール
Original Assignee
ハー・ルンドベック・アクチエゼルスカベット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/012781 external-priority patent/WO2020146527A1/en
Application filed by ハー・ルンドベック・アクチエゼルスカベット filed Critical ハー・ルンドベック・アクチエゼルスカベット
Publication of JP2022533030A publication Critical patent/JP2022533030A/ja
Publication of JP2022533030A5 publication Critical patent/JP2022533030A5/ja
Priority to JP2025174054A priority Critical patent/JP2026016471A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021564691A 2019-05-02 2020-02-18 抗ｃｇｒｐ抗体を用いた頭痛の治療 Pending JP2022533030A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025174054A JP2026016471A (ja) 2019-05-02 2025-10-16 抗ｃｇｒｐ抗体を用いた頭痛の治療

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962842162P 2019-05-02 2019-05-02
US62/842,162 2019-05-02
US201962872989P 2019-07-11 2019-07-11
US62/872,989 2019-07-11
USPCT/US2020/012781 2020-01-08
PCT/US2020/012781 WO2020146527A1 (en) 2019-01-08 2020-01-08 Acute treatment and rapid treatment of headache using anti-cgrp antibodies
PCT/US2020/018702 WO2020222892A1 (en) 2019-05-02 2020-02-18 Treatment of headache using anti-cgrp antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025174054A Division JP2026016471A (ja) 2019-05-02 2025-10-16 抗ｃｇｒｐ抗体を用いた頭痛の治療

Publications (2)

Publication Number Publication Date
JP2022533030A true JP2022533030A (ja) 2022-07-21
JP2022533030A5 JP2022533030A5 (enExample) 2023-02-06

Family

ID=73028680

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021564691A Pending JP2022533030A (ja) 2019-05-02 2020-02-18 抗ｃｇｒｐ抗体を用いた頭痛の治療
JP2025174054A Pending JP2026016471A (ja) 2019-05-02 2025-10-16 抗ｃｇｒｐ抗体を用いた頭痛の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025174054A Pending JP2026016471A (ja) 2019-05-02 2025-10-16 抗ｃｇｒｐ抗体を用いた頭痛の治療

Country Status (20)

Country Link
US (1) US20220251178A1 (enExample)
EP (1) EP3962522A4 (enExample)
JP (2) JP2022533030A (enExample)
KR (1) KR20220004053A (enExample)
CN (1) CN113811326A (enExample)
AU (1) AU2020267107B2 (enExample)
BR (1) BR112020027063A2 (enExample)
CA (1) CA3133571A1 (enExample)
CL (1) CL2021002866A1 (enExample)
DO (1) DOP2021000215A (enExample)
EA (1) EA202192865A1 (enExample)
GE (2) GEP20257803B (enExample)
IL (1) IL287759A (enExample)
JO (1) JOP20210247A1 (enExample)
MA (1) MA55815A (enExample)
MX (1) MX2021013426A (enExample)
PH (1) PH12021552422A1 (enExample)
SG (1) SG11202110637RA (enExample)
WO (1) WO2020222892A1 (enExample)
ZA (1) ZA202106627B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310885A (en) * 2021-08-27 2024-04-01 H Lundbeck As Treatment of cluster headache using anti-CGRP antibodies
KR20240058082A (ko) 2021-09-15 2024-05-03 하. 룬드벡 아크티에셀스카브 항-cgrp 항체 투약 및 스크리닝 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014517699A (ja) * 2011-05-20 2014-07-24 アルダーバイオ・ホールディングズ・エルエルシー 抗ｃｇｒｐ組成物およびその使用
WO2017186928A1 (en) * 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107827982B (zh) * 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
AU2015230933B2 (en) * 2014-03-21 2020-08-13 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
TWI799849B (zh) * 2015-04-24 2023-04-21 美商安美基公司 治療或預防偏頭痛之方法
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
CN109952314A (zh) * 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
WO2020146527A1 (en) * 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014517699A (ja) * 2011-05-20 2014-07-24 アルダーバイオ・ホールディングズ・エルエルシー 抗ｃｇｒｐ組成物およびその使用
WO2017186928A1 (en) * 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIANCA RAFFAELLI & UWE REUTER: "The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migr", NEUROTHERAPEUTICS, vol. 15, no. 2, JPN6023049821, 2018, pages 324 - 335, ISSN: 0005432302 *
PAUL L. DURHAM ET AL.: "Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists in the Treatment of Migraine", CNS DRUGS, vol. 24, no. 7, JPN6026002675, 2010, pages 539 - 548, ISSN: 0005778244 *
STEWART J. TEPPER: "CGRP and headache: a brief review", NEUROLOGICAL SCIENCES, vol. Vol.40, Suppl 1, JPN6023049822, 1 May 2019 (2019-05-01), pages 99 - 105, ISSN: 0005778243 *

Also Published As

Publication number Publication date
KR20220004053A (ko) 2022-01-11
MA55815A (fr) 2022-03-09
CL2021002866A1 (es) 2022-06-17
AU2020267107A1 (en) 2021-10-07
EP3962522A4 (en) 2023-07-19
BR112020027063A2 (pt) 2021-11-16
ZA202106627B (en) 2025-12-17
CA3133571A1 (en) 2020-11-05
IL287759A (en) 2022-01-01
JP2026016471A (ja) 2026-02-03
GEP20257803B (en) 2025-10-10
EA202192865A1 (ru) 2022-02-14
PH12021552422A1 (en) 2022-07-11
WO2020222892A1 (en) 2020-11-05
GEAP202515803A (en) 2025-06-10
EP3962522A1 (en) 2022-03-09
JOP20210247A1 (ar) 2023-01-30
US20220251178A1 (en) 2022-08-11
CN113811326A (zh) 2021-12-17
MX2021013426A (es) 2021-12-10
SG11202110637RA (en) 2021-10-28
AU2020267107B2 (en) 2026-04-09
DOP2021000215A (es) 2021-11-21

Similar Documents

Publication Publication Date Title
US12384836B2 (en) Treatment of headache using anti-CGRP antibodies
US20240343784A1 (en) Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies
JP2026016471A (ja) 抗ｃｇｒｐ抗体を用いた頭痛の治療
JP7628554B2 (ja) 抗ｃｇｒｐ抗体を用いた、片頭痛に関連する最も煩わしい症状（ｍｂｓ）の治療
US20250215069A1 (en) Treatment of cluster headache using anti-cgrp antibodies
KR20260030117A (ko) 병용 치료
AU2026202964A1 (en) Treatment of headache using anti-CGRP antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250408

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251016